Arch Biopartners Inc.
ACHFF
Rank in Stocks
#23154
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Share Price
$0.65206
Last synced: 2026-11-09
Market Cap
$45.22M
Change (1 day)
5.17%
Change (1 year)
-14.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Arch Biopartners Inc. (ACHFF)
Category
Healthcare
Operating Margin for Arch Biopartners Inc. (ACHFF)
Operating Margin as of November 2026 TTM: 0.00%
According to Arch Biopartners Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Arch Biopartners Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -186.00% | 9.99% |
| 2023 | -169.10% | 17.44% |
| 2022 | -143.99% | 380.45% |
| 2021 | -29.97% | -99.56% |
| 2020 | -6,826.15% | 205.88% |
| 2019 | -2,231.67% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -2,409.61% | 230.27% |
| 2014 | -729.58% | 43.79% |
| 2013 | -507.38% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | -100.00% |
| 2008 | -9.16% | -35.45% |
| 2007 | -14.19% | -446.94% |
| 2006 | 4.09% | -122.16% |
| 2005 | -18.46% | -53.64% |
| 2004 | -39.82% | 104.41% |
| 2003 | -19.48% | 754.39% |
| 2002 | -2.28% | -99.98% |
| 2001 | -11,436.95% | 3,884.72% |
| 2000 | -287.02% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Arch Biopartners Inc.'s operating margin
What was Arch Biopartners Inc.'s operating margin in 2025?
In 2025, Arch Biopartners Inc.'s operating margin was 0.00%, compared with -186.00% in 2024.
How has Arch Biopartners Inc.'s operating margin changed since 2020?
From 2020 to 2025, Arch Biopartners Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-6,826.15%).
How does Arch Biopartners Inc.'s operating margin compare with similar companies?
Arch Biopartners Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.